WAVE Life Sciences Ltd (NASDAQ:WVE) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

WAVE Life Sciences WVE is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for ...

B. Riley raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps a Buy rating on the shares following the ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

B.Riley Financial analyst Madison Elsaadi has reiterated their bullish stance on WVE stock, giving a Buy rating on October 31. Madison Elsaadi ...

Mirae Asset Global Investments Co. Ltd. lifted its stake in Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 23.4% ...

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective increased by research analysts at B. Riley from $19.00 to $22.00 in a note issued to investors on Monday, Benzinga reports.

PLANS TO HAVE FIVE GALNAC-RNA EDITING OR GALNAC-SIRNA PROGRAMS IN CLINIC BY 2026 * WAVE LIFE SCIENCES LTD: WVE-007 (INHBE GALNAC-SIRNA FOR OBESITY) IS ON TRACK TO INITIATE A CLINICAL TRIAL IN 1Q 2025 ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

Wave Life Sciences appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...

The heat has been out of the life sciences market over the last 18 months, but new VC investments could fuel a comeback for ...